|
|
LTA1 |
|
Vaxjo ID |
171 |
|
Vaccine Adjuvant Name |
LTA1 |
|
Adjuvant VO ID |
VO_0005355
|
|
Description |
A vaccine adjuvant made from the A subunit of heat-labile (LT) enterotoxin of Enterotoxigenic Escherichia coli (ETEC) that is able to induce Th1, Th2, and Th17 immune responses |
|
Stage of Development |
Research |
|
Location Licensed |
US (Tulane University) |
|
Host Species for Testing |
3 |
|
Components |
isolated enzymatic A1 domain of LT (heat-labile toxin) |
|
Storage |
-20C/-80C for long term |
|
Preparation |
remove B sub unit from LT |
|
Function |
Induces mucosal immunity, Induces epitope spreading, promotes antibody affinity maturation , Promotes antibody epitope spreading |
| References |
(Norton, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=44]
Norton et al., 2012: Norton EB, Lawson LB, Mahdi Z, Freytag LC, Clements JD. The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infection and immunity. 2012; 80(7); 2426-2435. [PubMed: 22526674].
|
|
